DUBLIN, Feb. 15, 2017 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the
"Company") today announced that it will release financial results
for the period ended December 31,
2016 after market close on Monday,
February 27, 2017.
An accompanying conference call will be held at 5:00 pm ET on February
27, 2017. To participate in the live call by
telephone, please dial (855) 296-9648 from the U.S., or (920)
663-6266 for international callers, using the confirmation code
56971538. Those interested in listening to the conference call live
via the internet may do so by visiting Theravance Biopharma's
website at www.theravance.com, under the Investor Relations
section, Presentations and Events. Please go to the website 15
minutes prior to the start of the call to register, download, and
install any necessary audio software.
A replay of the conference call will be available on Theravance
Biopharma's website for 30 days through March 29, 2017. An audio replay will also
be available through 8:00 pm ET on
March 6, 2017 by dialing (855)
859-2056 from the U.S., or (404) 537-3406 for international
callers, and then entering confirmation code 56971538.
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company
with the core purpose of creating medicines that help improve the
lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates
includes potential best-in-class medicines to address the unmet
needs of patients being treated for serious conditions primarily in
the acute care setting. VIBATIV® (telavancin), our first
commercial product, is a once-daily dual-mechanism antibiotic
approved in the U.S., Europe and
certain other countries for certain difficult-to-treat infections.
Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA)
being developed as a potential once-daily, nebulized treatment for
chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP)
inhibitor program is designed to develop selective NEP inhibitors
for the treatment of a range of major cardiovascular and renal
diseases, including acute and chronic heart failure, hypertension
and chronic kidney diseases, such as diabetic nephropathy. Our
research efforts are focused in the areas of inflammation and
immunology, with the goal of designing medicines that provide
targeted drug delivery to tissues in the lung and gastrointestinal
tract in order to maximize patient benefit and minimize risk. The
first program to emerge from this research is designed to develop
intestinally restricted pan-Janus kinase (JAK) inhibitors for the
treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments
that may be made by Glaxo Group Limited or one of its affiliates
(GSK) pursuant to its agreements with Innoviva, Inc. relating to
certain drug development programs, including the Closed Triple (the
combination of fluticasone furoate, umeclidinium, and vilanterol),
currently in development for the treatment of COPD and asthma.
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and
VIBATIV® are registered trademarks of the Theravance
Biopharma group of companies. Trademarks, trade names or service
marks of other companies appearing on this press release are the
property of their respective owners.
Contact Information:
Renee Gala
Chief Financial Officer
650-808-4045
investor.relations@theravance.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2016-financial-results-on-february-27-2017-300407324.html
SOURCE Theravance Biopharma, Inc.